Ratings Chong Kun Dang Holdings Corp.

Equities

A001630

KR7001630003

End-of-day quote Korea S.E. Other stock markets 23:00:00 02/05/2024 BST			5-day change	1st Jan Change
62,000 ^KRW	+0.32%		+0.81%	+4.73%

02-06	Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on August 12, 2022.	CI
02-06	Tranche Update on Chong Kun Dang Holdings Corp.'s Equity Buyback Plan announced on August 12, 2022.	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

The company's share price in relation to its net book value makes it look relatively cheap.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company benefits from high valuations in earnings multiples.

Ratings chart - Surperformance

Sector: Food Processing

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CHONG KUN DANG HOLDINGS CORP.	+4.73%	218M		-
ZHEJIANG NHU COMPANY LTD.	+13.21%	8.15B		D+
BELLRING BRANDS, INC.	+3.16%	7.52B		C-
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+12.30%	6.65B		-
THE SIMPLY GOOD FOODS COMPANY	-5.71%	3.73B		B-
BYHEALTH CO., LTD	-6.99%	3.72B		D
XIAMEN KINGDOMWAY GROUP COMPANY	-4.78%	1.31B	-	-
SIRIO PHARMA CO., LTD.	+12.61%	972M		-
HERBALIFE LTD.	-37.22%	958M		B+
USANA HEALTH SCIENCES, INC.	-15.02%	876M		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes